Page 36 - Hal Barron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GlaxoSmithKline plc (GSK) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. GlaxoSmithKline plc (NYSE: GSK) Operator Good afternoon, ladies and gentlemen. And welcome to the Analyst Call on the GSK First Quarter 2021 Results. I will now hand you over to Iain Mackay, our CFO, who will introduce today's session.SPONSORED: 10 stocks we like better than GlaxoSmithKline When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a deca...

GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer AnaptysBio earns a $20m milestone payment on approval after originally developing the drug British pharma company GlaxoSmithKline (GSK) has received US approval for its PD-1 inhibitor Jemperli for the treatment of endometrial cancer. The Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, following an FDA-approved test. Cells that are mismatch repair (MMR) deficient often have many ...

GlaxoSmithKline receives US approval for endometrial cancer treatment The trial showed an overall response rate of 42.3% and a duration of response of six months or more for 93.3% of participants GlaxoSmithKline PLC (LON:GSK) said the US Food and Drug Administration (FDA) has approved its treatment for adults with recurrent or advanced endometrial cancer. JEMPERLI (dostarlimab-gxly) is an antibody that blocks the interaction between the PD-1 receptor with two other proteins that suppress the immune system. This indication is approved under accelerated approval based on tumour response rate an...

GlaxoSmithKline's Jemperli secures EU approval following US thumbs up Fri, 23rd Apr 2021 16:08 (Alliance News) - GlaxoSmithKline PLC said Friday the European Commission has approved Jemperli for for women with recurrent or advanced dMMR endometrial cancer. Shares in the blue-chip pharma firm were down 0.7% in London on Friday afternoon at 1,339.00 pence each. The EU's approval follows the regulators in the US green-lighting the treatment on Thursday. Dostarlimab, the medical name for Jemperli, is indicated for the treatment of adult patients with mismatch repair deficient, dMMR, recurrent or...

Share this article Share this article LONDON, April 22, 2021 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company's Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen. This ...